Marshall Wace North America’s Aerie Pharmaceuticals AERI Stock Holding History

Marshall Wace North America’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-41,231	Closed	-$608K	–	1561
2020 Q2	$608K	Buy	41,231 +4,624	+13%	+$68.4K	﹤0.01%	883
2020 Q1	$494K	Buy	+36,607	New	+$695K	﹤0.01%	756
2019 Q4	–	Sell	-2,203	Closed	-$42K	–	1702
2019 Q3	$42K	Buy	+2,203	New	+$50.5K	﹤0.01%	1181
2019 Q2	–	Sell	-95,578	Closed	-$4.54M	–	1759
2019 Q1	$4.54M	Buy	95,578 +16,405	+21%	+$722K	0.03%	343
2018 Q4	$2.86M	Buy	79,173 +27,651	+54%	+$1.3M	0.03%	360
2018 Q3	$3.17M	Sell	51,522 -46,106	-47%	-$2.96M	0.02%	403
2018 Q2	$6.59M	Buy	+97,628	New	+$5.46M	0.04%	447
2018 Q1	–	Sell	-28,206	Closed	-$1.69M	–	1782
2017 Q4	$1.69M	Buy	28,206 +7,790	+38%	+$472K	0.01%	879
2017 Q3	$1M	Buy	+20,416	New	+$1.11M	0.01%	948

Other funds holding AERI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

LCS

Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return

Marshall Wace North America's AERI Position: Q3 2020 in Review

Marshall Wace North America sold out of Aerie Pharmaceuticals (AERI) in Q3 2020, closing a stake of 41,231 shares — an estimated $608K sold.

Marshall Wace North America first reported a position in AERI in Q3 2017 and held it in 9 quarters. The position peaked at $6.59M in Q2 2018. 148 funds tracked by Wall St. Rank hold AERI as of Q3 2020.

Marshall Wace North America reported no remaining Aerie Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Marshall Wace North America sold 41,231 Aerie Pharmaceuticals shares in Q3 2020, an estimated $608K.
Marshall Wace North America first reported a position in Aerie Pharmaceuticals in Q3 2017 and held it in 9 quarters.
Marshall Wace North America's Aerie Pharmaceuticals position peaked at $6.59M in Q2 2018.
148 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q3 2020.

Based on Marshall Wace North America's 13F filing for Q3 2020, filed 16 Nov 2020.